RANDOMIZED. DOUBLE-BLIND, PHASE III TRIAL OF STANDARD ANTIEMETIC THERAPY COMBINED WITH A SINGLE ORAL, A 3-DAY ORAL, OR A 3-DAY IV/ORAL REGIMEN OF CASOPITANT, A NOVEL NEUROKININ-1 (NK-1) RECEPTOR ANTAGONIST, IN PATIENTS (PTS) RECEIVING MODERATELY EMETOGENIC CHEMOTHERAPY (MEC)

被引：0

作者：

Herrstedt, J. ^{[1
]}

Roila, F. ^{[2
]}

Van Belle, S. ^{[3
]}

Levin, J. ^{[4
]}

Grunberg, S. M. ^{[5
,6
]}

机构：

[1] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark

[2] Silvestrini Hosp, Div Med Oncol, Perugia, Italy

[3] Ghent Univ Hosp, Dept Med Oncol, B-9000 Ghent, Belgium

[4] GlaxoSmithKline Inc, Philadelphia, PA USA

[5] Univ Vermont, Dept Med, Burlington, VT USA

[6] Univ Vermont, Dept Oncol, Burlington, VT USA

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：272 / 272

页数：1

共 19 条

[1] Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)
Aziz, Z.
Arpornwirat, W.
Herrstedt, J.
Camlett, I.
Piontek, T.
Ranganathan, S.
Schnyder, J.
Bandekar, R. R.
Levin, J.
Shaharyar, A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[2] Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)
Grunberg, S. M.
Aziz, Z.
Shaharyar, A.
Herrstedt, J.
Roila, F.
VanBelle, S.
Bandekar, R. R.
Guckert, M. E.
Russo, M. W.
Arpornwirat, W.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[3] PHASE III RESULTS OF A SINGLE ORAL AND A 3-DAY IV/ORAL DOSING REGIMEN FOR THE NOVEL NEUROKININ-1 (NK-1) RECEPTOR ANTAGONIST, CASPOPITANT (CAS), IN THE PREVENTION OF CINV IN PATIENTS (PTS) RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC)
Grunberg, M.
Russo, M.
Wright, O. J.
Camlett, I. I.
Herrstedt, J.
[J]. ANNALS OF ONCOLOGY, 2008, 19 : 273 - 273
[4] Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC)
Herrstedt, J.
Grunberg, S.
Rolski, J.
Bandekar, R. R.
Guckert, M. E.
Camlett, I.
Russo, M. W.
Strausz, J.
Aziz, Z.
Thorn, S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[5] Safety and efficacy of the novel antiemetic neurokinin-1 (NK-1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) - subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial
Herrstedt, J.
Arpornwirat, W.
Albert, I.
Hansen, V. L.
Bandekar, R. R.
Levin, J.
Grunberg, S. M.
[J]. EJC SUPPLEMENTS, 2008, 6 (07): : 196 - 197
[6] Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
Herrstedt, Jorn
Apornwirat, Wichit
Shaharyar, Ahmed
Aziz, Zeba
Roila, Fausto
Van Belle, Simon
Russo, Mark W.
Levin, Jeremey
Ranganathan, Salabha
Guckert, Mary
Grunberg, Steven M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) : 5363 - 5369
[7] Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC).
Arpornwirat, W.
Albert, I.
Hansen, V. L.
Russo, M. A.
Ross, G. A.
Pence, C. D.
Bandekar, R. R.
Grunberg, S. M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 471S - 471S
[8] Phase II clinical trial overview of the novel neurokinin-1 (NK-1) antagonist, casopitant, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and highly emetogenic chemotherapy
Rogers, Miriam
Pence, Christine
Russo, Mark
[J]. ONCOLOGY NURSING FORUM, 2008, 35 (03) : 557 - 557
[9] Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC).
Rolski, J.
Ramlau, R.
Dediu, M.
Russo, M. W.
Ross, G. A.
Mather, R. A.
Bandekar, R. R.
Grunberg, S. M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 471S - 471S
[10] Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC)
Schnadig, Ian D.
Modiano, Manuel R.
Poma, Allen
Hedley, Mary Lynne
Martell, Robert E.
Schwartzberg, Lee Steven
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 →